Table 4A

CAPS secondary trial analyses: mean or median values, with linear model coefficient estimates (95% CI) for continuous outcomes

InterventionControlIntervention versus controlP value
FEV1, mean (SD) L*1.02 (0.18)0.97 (0.19)0.02 (−0.01 to 0.06)0.135
FVC, mean (SD) L*1.16 (0.21)1.09 (0.21)0.04 (0.00 to 0.07)0.033
FEV1/FVC, mean (SD) *0.88 (0.06)0.89 (0.06)−0.01 (−0.02 to 0.01)0.411
%COHb, median (IQR)†‡3.50 (1.00 to 6.00)4.85 (2.00 to 7.00)−0.89 (−1.53 to −0.26)0.006
Mean CO ppm, median (IQR)§‡¶**0.18 (0.05 to 0.55)0.20 (0.08 to 0.52)0.03 (−0.35 to 0.42)0.857
Weight-for-age z-score, mean (SD)†−1.20 (0.89)−1.06 (0.85)−0.13 (−0.29 to 0.02)0.096
Height-for-age z-score, mean (SD)†−1.10 (0.84)−1.06 (0.93)−0.04 (−0.20 to 0.12)0.624
MUAC, mean (SD) cm††15.92 (1.29)15.94 (1.30)−0.02 (−0.26 to 0.21)0.846
  • *Spirometry data for 300 participants; 167 intervention, 133 control. FEV1, FVC and FEV1/FVC adjusted for age, sex, height and weight in regression model.

  • †COHb, height and weight data for 476 participants; 260 intervention, 216 control.

  • ‡Adjusted for seasonality in linear regression model.

  • §24 hours CO monitoring for 436 participants; 239 intervention, 197 control.

  • ¶Log10 CO values used in linear regression model.

  • **Mean exposure was estimated over the monitoring period per individual, the median of these values (and IQR) is presented for the study population.

  • ††MUAC for 466 participants; 260 intervention, 206 control.

  • CO, carbon monoxide; COHb, carboxyhaemoglobin level; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MUAC, mid-upper arm circumference.